Clinical Trials Market Size To Hit US$ 84.43 Billion By 2030

The global clinical trials market size is expected to hit around USD 84.43 billion by 2030 and progressing a CAGR of 5.7% over the forecast period 2022 to 2030.

Clinical Trials Market Size 2020-2030

The on clinical trials Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.

Download Free Sample@ https://www.precedenceresearch.com/sample/1185

Report Scope of the Clinical Trials Market

Report Highlights	Details
Market Size	USD 84.43 Billion by 2030
Growth Rate	CAGR of 5.7% from 2022 to 2030
Largest Market	North America
Fastest Growing Market	Asia Pacific
Base Year	2021
Forecast Period	2022 to 2030
Segments Covered	Phase, Study Design, Indication

A recent report provides crucial insights along with application based and forecast information in the Global Clinical trials Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Clinical trials market.

A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.

Companies and Manufacturers Covered

The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Clinical trials market are included as given below:

Clinical trials Market Key Players

arexel
IQVIA
Charles River Laboratory
Omnicare
Kendle
Chiltern
Pharmaceutical Product Development, LLC

Market Segments

By Phase

Phase 1
Phase 2
Phase 3
Phase 4

By Study Design

Observational
Interventional
Expanded Access

By Indication

Autoimmune/Inflammation
- Rheumatoid arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome (IBS)
- Others
Pain Management
- Chronic Pain
- Acute Pain
Oncology
- Blood Cancer
- Solid Tumors
- Other
CNS Condition
- Epilepsy
- Parkinson's Disease (PD)
- Huntington's Disease
- Stroke
- Traumatic Brain Injury (TBI)
- Amyotrophic Lateral Sclerosis (ALS)
- Muscle Regeneration
- Others
Diabetes
Obesity
Cardiovascular
Others

By Service Type

Protocol Designing
Patient Recruitment
Laboratory Services
Site Identification
Bioanalytical Testing Services
- Cell-based Assays
- Virology Testing
- Method Development, Optimization, & Validation
- Serology, Immunogenicity, & Neutralizing Antibodies
- Biomarker Testing Services
- PK/PD (Pharmacokinetics/Pharmacodynamics) Testing Services
- Other Bioanalytical Testing Services
Analytical Testing Services
Clinical Trial Supply & Logistic Services
Clinical Trial Data Management Services
Decentralized Clinical Services
Medical Device Testing Services
Others

By Sponsor

Pharmaceutical & Biopharmaceutical Companies
Medical Device Companies
Others

By End User

Hospital
Laboratories
Clinics

By Application

Vaccine
Cell & Gene Therapy
Small Molecules
Other Applications

By Geography

North America

U.S.
Canada

Europe

Germany
France
United Kingdom
Rest of Europe

Asia Pacific

China
Japan
India
Southeast Asia
Rest of Asia Pacific

Latin America

Brazil
Rest of Latin America

Middle East & Africa (MEA)

GCC
North Africa
South Africa
Rest of Middle East & Africa

Report Objectives

To define, describe, and forecast the global clinical trials market based on product, and region
To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the clinical trials market

Table of Content

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Clinical Trials Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Clinical Trials Market

5.1. Covid-19: Clinical Trials Industry Impact
5.2. Clinical Trials Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Clinical Trials Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Clinical Trials Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Clinical Trials Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Growing prevalence of chronic disorders
6.1.1.2. Increasing number of clinical trials in developing regions
6.1.2. Market Restraints
6.1.2.1. Rigorous guidelines
6.1.3. Market Opportunities
6.1.3.1. Increasing demand for advanced treatments such as personalized medicines
6.1.3.2. Technological advancements

Chapter 7. Global Clinical Trials Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Clinical Trials Market Revenue by Market Players (2016 -2019)
7.1.1.2. Clinical Trials Market Revenue Market Share by Market Players (2016 -2019)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Phase Portfolio Expansion, Geographic Expansion, Phase Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Clinical Trials Market, By Phase

8.1. Clinical Trials Market, by Phase, 2019 - 2030
8.1.1. Phase 1
8.1.1.1. Market Revenue and Forecast (2019 - 2030)
8.1.2. Phase 2
8.1.2.1. Market Revenue and Forecast (2019 - 2030)
8.1.3. Phase 3
8.1.3.1. Market Revenue and Forecast (2019 - 2030)
8.1.4. Phase 4
8.1.4.1. Market Revenue and Forecast (2019 - 2030)

Chapter 9. Global Clinical Trials Market, By Study Design

9.1. Clinical Trials Market, by Study Design, 2019 - 2030
9.1.1. Observational
9.1.1.1. Market Revenue and Forecast (2019 - 2030)
9.1.2. Interventional
9.1.2.1. Market Revenue and Forecast (2019 - 2030)
9.1.3. Expanded Access
9.1.3.1. Market Revenue and Forecast (2019 - 2030)

Chapter 10. Global Clinical Trials Market, By Indication

10.1. Clinical Trials Market, by Indication, 2019 - 2030
10.1.1. Oncology
10.1.1.1. Market Revenue and Forecast (2019 - 2030)
10.1.2. Autoimmune/Inflammation
10.1.2.1. Market Revenue and Forecast (2019 - 2030)
10.1.3. Diabetes
10.1.3.1. Market Revenue and Forecast (2019 - 2030)
10.1.4. Central Nervous System
10.1.4.1. Market Revenue and Forecast (2019 - 2030)
10.1.5. Cardiovascular
10.1.5.1. Market Revenue and Forecast (2019 - 2030)
10.1.6. Pain Management
10.1.7. Market Revenue and Forecast (2019 - 2030)
10.1.8. Others
10.1.8.1. Market Revenue and Forecast (2019 - 2030)

Chapter 11. Global Clinical Trials Market, Regional Estimates and Trend Forecast

11.1. North America
11.1.1. Market Revenue Forecast by Phase(2019 - 2030)
11.1.2. Market Revenue Forecast by Study Design(2019 - 2030)
11.1.3. Market Revenue Forecast by Indication (2019 - 2030)
11.1.4. U.S
11.1.4.1. Market Revenue Forecast (2019 - 2030)
11.1.5. Canada
11.1.5.1. Market Revenue Forecast (2019 - 2030)
11.2. Europe
11.2.1. Market Revenue Forecast by Phase (2019 - 2030)
11.2.2. Market Revenue Forecast by Study Design (2019 - 2030)
11.2.3. Market Revenue Forecast by Indication (2019 - 2030)
11.2.4. UK
11.2.4.1. Market Revenue Forecast (2019 - 2030)
11.2.5. Germany
11.2.5.1. Market Revenue Forecast (2019 - 2030)
11.2.6. France
11.2.6.1. Market Revenue Forecast (2019 - 2030)
11.2.7. Rest of EU
11.2.7.1. Market Revenue Forecast (2019 - 2030)
11.3. Asia Pacific (APAC)
11.3.1. Market Revenue Forecast by Phase (2019 - 2030)
11.3.2. Market Revenue Forecast by Study Design (2019 - 2030)
11.3.3. Market Revenue Forecast by Indication (2019 - 2030)
11.3.4. China
11.3.4.1. Market Revenue Forecast (2019 - 2030)
11.3.5. India
11.3.5.1. Market Revenue Forecast (2019 - 2030)
11.3.6. Japan
11.3.6.1. Market Revenue Forecast (2019 - 2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue Forecast (2019 - 2030)
11.4. LATAM
11.4.1. Market Revenue Forecast by Phase (2019 - 2030)
11.4.2. Market Revenue Forecast by Study Design (2019 - 2030)
11.4.3. Market Revenue Forecast by Indication (2019 - 2030)
11.4.4. Brazil
11.4.4.1. Market Revenue Forecast (2019 - 2030)
11.4.5. Rest of LATAM
11.4.5.1. Market Revenue Forecast (2019 - 2030)
11.5. Middle East and Africa (MEA)
11.5.1. Market Revenue Forecast by Phase (2019 - 2030)
11.5.2. Market Revenue Forecast by Study Design (2019 - 2030)
11.5.3. Market Revenue Forecast by Indication (2019 - 2030)
11.5.4. GCC
11.5.4.1. Market Revenue Forecast (2019 - 2030)
11.5.5. North Africa
11.5.5.1. Market Revenue Forecast (2019 - 2030)
11.5.6. South Africa
11.5.6.1. Market Revenue Forecast (2019 - 2030)
11.5.7. Rest of MEA
11.5.7.1. Market Revenue Forecast (2019 - 2030)

Chapter 12. Company Profiles

12.1. Parexel
12.1.1. Company Overview, Business Information, Regional Presence
12.1.2. Phase Portfolio Analysis
12.1.2.1. Product Details, Specification, Indication
12.1.3. Revenue, Price, and Gross Margin (2019 - 2020)
12.1.4. Recent Developments and Strategies
12.2. IQVIA
12.2.1. Company Overview, Business Information, Regional Presence
12.2.2. Phase Portfolio Analysis
12.2.2.1. Product Details, Specification, Indication
12.2.3. Revenue, Price, and Gross Margin (2019 - 2020)
12.2.4. Recent Developments and Strategies
12.3. Charles River Laboratory
12.3.1. Company Overview, Business Information, Regional Presence
12.3.2. Phase Portfolio Analysis
12.3.2.1. Product Details, Specification, Indication
12.3.3. Revenue, Price, and Gross Margin (2019 - 2020)
12.3.4. Recent Developments and Strategies
12.4. Omnicare
12.4.1. Company Overview, Business Information, Regional Presence
12.4.2. Phase Portfolio Analysis
12.4.2.1. Product Details, Specification, Indication
12.4.3. Revenue, Price, and Gross Margin (2019 - 2020)
12.4.4. Recent Developments and Strategies
12.5. Kendle
12.5.1. Company Overview, Business Information, Regional Presence
12.5.2. Phase Portfolio Analysis
12.5.2.1. Product Details, Specification, Indication
12.5.3. Revenue, Price, and Gross Margin (2019 - 2020)
12.5.4. Recent Developments and Strategies
12.6. Chiltern
12.6.1. Company Overview, Business Information, Regional Presence
12.6.2. Phase Portfolio Analysis
12.6.2.1. Product Details, Specification, Indication
12.6.3. Revenue, Price, and Gross Margin (2019 - 2020)
12.6.4. Recent Developments and Strategies
12.7. Pharmaceutical Product Development, LLC
12.7.1. Company Overview, Business Information, Regional Presence
12.7.2. Phase Portfolio Analysis
12.7.2.1. Product Details, Specification, Indication
12.7.3. Revenue, Price, and Gross Margin (2019 - 2020)
12.7.4. Recent Developments and Strategies
12.8. Company 8
12.8.1. Company Overview, Business Information, Regional Presence
12.8.2. Phase Portfolio Analysis
12.8.2.1. Product Details, Specification, Indication
12.8.3. Revenue, Price, and Gross Margin (2019 - 2020)
12.8.4. Recent Developments and Strategies
12.9. Company 9
12.9.1. Company Overview, Business Information, Regional Presence
12.9.2. Phase Portfolio Analysis
12.9.2.1. Product Details, Specification, Indication
12.9.3. Revenue, Price, and Gross Margin (2019 - 2020)
12.9.4. Recent Developments and Strategies
12.10. Company 10
12.10.1. Company Overview, Business Information, Regional Presence
12.10.2. Phase Portfolio Analysis
12.10.2.1. Product Details, Specification, Indication
12.10.3. Revenue, Price, and Gross Margin (2019 - 2020)
12.10.4. Recent Developments and Strategies